| Followers | 238 |
| Posts | 15469 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Saturday, September 10, 2016 8:22:04 PM
Anyway, I just wanted to share with some others who might be considering an entry investment that I waded in and I will continue to purchase shares if/as there are continued rounds. With the optionality of combo trials, the risk reward is compelling. - lattices
Thank you for sharing lattices... and for one, I'm glad you've put some on the table. Personally, I think failure has pretty much been baked into share the price plus some. Yes, it could continue to spiral downwards if the company is forced to do yet another dilutive type of financing without significant news (although last Tuesday's news was really good, IMO). But the price is here because whose with enough shares to sell back and forth expect failure. And they are, at the very least, just here to help it along.
But... patients are all living longer, according to Linda Liau. And according to her, the comparison really boils down to this:
So in reality, I think, you know, what we’re really comparing now is actually early DC Vaccination versus later DC Vaccination (big smile). - Linda Liau
And if there's a big enough difference between these two subgroups, well... what to do, what to do? Each of the four countries (US, UK, Germany and Canada) will approach the data, when presented, in their own special way. Like Linda P says, there are four ways to win here.
Anyway, I wouldn't worry yourself over what some on this board might think... if you feel like communicating or have something to share, I hope you will do so.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
